Sex Differences in Type-2 Diabetes: Implications for Cardiovascular Risk Management

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the leading cause of death in individuals with type 2 diabetes (T2DM).
• Sex and gender differences (SGDs) significantly impact CVD risk in T2DM, necessitating specialized preventive strategies for women.
• Women with T2DM may experience delayed diagnosis, receive less therapeutic support, and achieve treatment goals less frequently than men.

Purpose of the Study:

• To analyze the influence of diabetes on CVD risk from a sex and gender perspective.
• To review SGDs in CVD primary and secondary prevention strategies, including antiplatelet drugs and statins.

Main Methods:

• Review of existing literature on sex and gender differences in T2DM and CVD.
• Analysis of evidence regarding the efficacy of antiplatelet agents and statins in CVD prevention for diabetic populations.
• Examination of gender-specific recommendations for CVD primary prevention.

Main Results:

• Antiplatelet drugs (ASA) and statins are effective in secondary CVD prevention for both sexes with T2DM.
• Primary CVD prevention with ASA may require sex-specific age cut-offs.
• Statin use in women for primary prevention needs careful monitoring for myalgia and potential diabetes development.

Conclusions:

• A gender-informed approach to CVD prevention is essential for reducing adverse cardiovascular events in individuals with T2DM.
• Addressing SGDs in prevention strategies can improve cardiovascular outcomes for diabetic women.